* Avanos Medical Inc AVNS.N AVNS.K is expected to show a
fall
in quarterly revenue when it reports results on August 9.
* The Alpharetta Georgia-based company is expected to
report a
8.3% decrease in revenue to $186.225 million from $203 million a
year ago, according to the mean estimate from 4 analysts, based
on Refinitiv data.
* Refinitiv's mean analyst estimate for Avanos Medical Inc
is for
earnings of 30 cents per share.
* The current average analyst rating on the shares is "hold"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 3
"hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Avanos
Medical
Inc is $31, above its last closing price of $24.20.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Mar. 31 2023 0.27 0.27 0.27 Met -1.5
Dec. 31 2023 0.49 0.49 0.60 Beat 22.4
Sep. 30 2022 0.35 0.35 0.38 Beat 7.8
Jun. 30 2022 0.38 0.38 0.41 Beat 7.3
Mar. 0.26 0.26 0.26 Met 0
31 2022
Dec. 31 2021 0.40 0.40 0.46 Beat 14.4
Sep. 30 2021 0.29 0.30 0.25 Missed -17.1
Jun. 30 2021 0.23 0.23 0.21 Missed -10
This summary was machine generated August 7 at 15:18 GMT. All
figures in US dollars unless otherwise stated